Lv3
300 积分 2024-02-18 加入
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
7天前
已完结
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma
1个月前
已完结
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
4个月前
已完结
Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review
4个月前
已完结
P3.18.59 Resistance Mechanisms and Sequential Therapies Following 1St Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)
4个月前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
6个月前
已完结
Comprehensive management strategies for amivantamab-induced toxicities and review of the literature
7个月前
已完结
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
7个月前
已完结
皖公网安备34019202002308
